PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24621868-3	2013	Some of the benefits seen with hydralazine, including afterload reduction and attenuation of nitrate tolerance, have also been observed with angiotensin-converting enzyme inhibitors.	Hydralazine	31-42	angiotensin I converting enzyme	Homo sapiens	141-170	
8890799-6	1996	In studies of long-term vasodilator therapy in patients with chronic aortic regurgitation, a reduction in left ventricular volumes and regurgitant fraction, with or without an increase in ejection fraction, has been observed during treatment with hydralazine, nifedipine and ACE inhibitors.	Hydralazine	247-258	angiotensin I converting enzyme	Homo sapiens	275-278	
16004861-7	2005	Recently, the combination of isosorbide dinitrate and hydralazine has been demonstrated to improve survival in African Americans with New York Heart Association class III and IV heart failure, and represents an adjunctive treatment option when added to standard medical therapy consisting of ACE inhibitors, beta blockers, digoxin, diuretics, and aldosterone antagonists.	Hydralazine	54-65	angiotensin I converting enzyme	Homo sapiens	292-295	
12729848-10	2003	The combination of hydralazine and isosorbide dinitrate might be useful in patients (especially in African Americans) who cannot tolerate ACE inhibitors or valsartan because of hypotension or renal dysfunction.	Hydralazine	19-30	angiotensin I converting enzyme	Homo sapiens	138-141	
9452775-8	1997	In the case of contraindication or impossibility of using angiotensin converting enzyme inhibitors, a combination of high doses of nitrates and hydralazine may be justified.	Hydralazine	144-155	angiotensin I converting enzyme	Homo sapiens	58-87	
19198701-5	2008	In a racially mixed population, treatment with a combination of ISDN and hydralazine reduced mortality compared to placebo to a nearly statistically significant extent in the first Vasodilator Heart Failure Trial (V-HeFT I) but was inferior to treatment with angiotensin-converting enzyme (ACE) inhibitor enalapril in the V-HeFT II study.	Hydralazine	73-84	angiotensin I converting enzyme	Homo sapiens	259-288	
19198701-5	2008	In a racially mixed population, treatment with a combination of ISDN and hydralazine reduced mortality compared to placebo to a nearly statistically significant extent in the first Vasodilator Heart Failure Trial (V-HeFT I) but was inferior to treatment with angiotensin-converting enzyme (ACE) inhibitor enalapril in the V-HeFT II study.	Hydralazine	73-84	angiotensin I converting enzyme	Homo sapiens	290-293	
17375804-1	2007	The African American Heart Failure Trial (A-HeFT) found that African American patients with advanced heart failure fared better if the fixed-dose combination of isosorbide dinitrate and hydralazine was added to their regimen, which for most of them already included an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB), a beta-blocker, and a diuretic (N Engl J Med 2004; 351:2049-2057).	Hydralazine	186-197	angiotensin I converting enzyme	Homo sapiens	269-298	
17375804-1	2007	The African American Heart Failure Trial (A-HeFT) found that African American patients with advanced heart failure fared better if the fixed-dose combination of isosorbide dinitrate and hydralazine was added to their regimen, which for most of them already included an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB), a beta-blocker, and a diuretic (N Engl J Med 2004; 351:2049-2057).	Hydralazine	186-197	angiotensin I converting enzyme	Homo sapiens	300-303	
11096488-7	1999	The combination of hydralazine and isosorbide dinitrate is an acceptable alternative therapy for patients who cannot take ACE inhibitors.	Hydralazine	19-30	angiotensin I converting enzyme	Homo sapiens	122-125	
8754362-9	1996	For patients who cannot take an ACE inhibitor the combination of hydralazine and nitrates may offer some prognostic benefit.	Hydralazine	65-76	angiotensin I converting enzyme	Homo sapiens	32-35	
7554808-8	1995	Oral isosorbide dinitrate plus hydralazine improves survival in patients with CHF, and should be administered to patients with CHF and abnormal or normal LV ejection fraction who cannot tolerate ACE inhibitor therapy or in whom CHF persists despite therapy with diuretics plus ACE inhibitors.	Hydralazine	31-42	angiotensin I converting enzyme	Homo sapiens	277-280	
7933398-13	1994	Isosorbide dinitrate and hydralazine hydrochloride should be tried in patients who cannot tolerate ACE inhibitors or who have refractory symptoms.	Hydralazine	25-50	angiotensin I converting enzyme	Homo sapiens	99-102